Cost-effectiveness of de-escalation from micafungin versus escalation from fluconazole for invasive candidiasis in China

References

• Ruhnke M. Antifungal stewardship in invasive Candida infections. Clin Microbiol Infect 2014;20(Suppl 6):11-18
   PubMed Web of Science ®Google Scholar
• Bassetti M, Mikulska M, Viscoli C. Bench-to-bedside review: therapeutic management of invasive candidiasis in the intensive care unit. Crit Care 2010;14:244
   PubMed Web of Science ®Google Scholar
• Cheng B, Xie G, Yao S, et al. Epidemiology of severe sepsis in critically ill surgical patients in ten university hospitals in China. Crit Care Med 2007;35:2538-46
   PubMed Web of Science ®Google Scholar
• Charlier C, Hart E, Lefort A, et al. Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J Antimicrob Chemother 2006;57:384-410
   PubMed Web of Science ®Google Scholar
• Quindos G. Epidemiology of candidaemia and invasive candidiasis. A changing face. Rev Iberoam Micol 2014;31:42-8
   PubMed Web of Science ®Google Scholar
• Falagas M, Roussos N, Vardakas K. Relative frequency of albicans and the various non albicans Candida spp among candidemia isolates from inpatients in various parts of the world: a systematic review. Int J Infect Dis 2010;14:e954-66
   PubMed Web of Science ®Google Scholar
• Gong X, Luan T, Wu X, et al. Invasive candidiasis in intensive care units in China: risk factors and prognoses of Candida albicans and non-albicans Candida infections. Am J Infect Control 2016;44:e59-63
   PubMed Web of Science ®Google Scholar
• Slavin MA, Sorrell TC, Marriott D, et al. Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death. J Antimicrob Chemother 2010;65:1042-51
   PubMed Web of Science ®Google Scholar
• Sucher AJ, Chahine EB, Balcer HE. Echinocandins: the newest class of antifungals. Ann Pharmacother 2009;43:1647-57
   PubMed Web of Science ®Google Scholar
• Messer SA, Diekema DJ, Boyken L, et al. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp. J Clin Microbiol 2006;44:324-6
   PubMed Web of Science ®Google Scholar
• Chen SC, Slavin MA, Sorrell TC. Echinocandin antifungal drugs in fungal infections: a comparison. Drugs 2011;71:11-41
   PubMed Web of Science ®Google Scholar
• Cornely OA, Bassetti M, Calandra T, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 2012;18(Suppl 7):19-37
   PubMed Web of Science ®Google Scholar
• Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016;62:e1-50
   PubMed Web of Science ®Google Scholar
• Masterton RG, Casamayor M, Musingarimi P, et al. De-escalation from micafungin is a cost effective alternative to traditional escalation from fluconazole in the treatment of patients with systemic Candida infections. J Med Econ 2013;16:1344-56
   PubMedGoogle Scholar
• Arnold HM, Micek ST, Shorr AF, et al. Hospital resource utilization and costs of inappropriate treatment of candidemia. Pharmacotherapy 2010;30:361-8
   PubMed Web of Science ®Google Scholar
• Zilberberg MD, Kollef MH, Arnold H, et al. Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: a retrospective cohort study. BMC Infect Dis 2010;10:150
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ, Sheehan DJ. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev 2006;19:435-47
   PubMed Web of Science ®Google Scholar
• Liu W, Tan J, Sun J, et al. Invasive candidiasis in intensive care units in China: in vitro antifungal susceptibility in the China-SCAN study. J Antimicrob Chemother 2014;69:162-7
   PubMed Web of Science ®Google Scholar
• Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007;369:1519-27
   PubMed Web of Science ®Google Scholar
• Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007;45:883-93
   PubMed Web of Science ®Google Scholar
• Kubiak DW, Bryar JM, McDonnell AM, et al. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis. Clin Ther 2010;32:637-48
   PubMed Web of Science ®Google Scholar
• Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994;331:1325-30
   PubMed Web of Science ®Google Scholar
• Anaissie EJ, Darouiche RO, Abi-Said D, et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 1996;23:964-72
   PubMed Web of Science ®Google Scholar
• Phillips P, Shafran S, Garber G, et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Eur J Clin Microbiol Infect Dis 1997;16:337-45
   PubMed Web of Science ®Google Scholar
• Sipsas NV, Lewis RE, Tarrand J, et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001–2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer 2009;115:4745-52
   PubMed Web of Science ®Google Scholar
• Marfo K, Guo Y. Pharmacoeconomic analysis of micafungin (Mycamine) 100 mg and 150 mg daily in the treatment of candidemia. P T 2009;34:196-9
   PubMedGoogle Scholar
• Shanghai Pharmaceutical Trade Association. Drugs’ price information in Shanghai. Shanghai, PR China. 2015. Available at: http://www.spta.cn/front/news.do?id =12793
   Google Scholar
• Xie GH, Fang XM, Fang Q, et al. Impact of invasive fungal infection on outcomes of severe sepsis: a multicenter matched cohort study in critically ill surgical patients. Crit Care 2008;12:R5
   PubMed Web of Science ®Google Scholar
• Diekema DJ, Messer SA, Brueggemann AB, et al. Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol 2002;40:1298-302
   PubMed Web of Science ®Google Scholar
• Health Protection Authority. Health Protection Report: Weekly Report; London, UK. 2008. Available at: http://webarchive.nationalarchives.gov.uk/
   Google Scholar
• National Bureau of Statistics of the People’ Republic of China. Healthcare consumer CPI of the People’s Republic of China; Beijing, PR China. 2014. Available at: http://data.stats.gov.cn/search.htm?s=CPI
   Google Scholar
• Beijing Municipal People’s Government. Data on file. Beijing basic medical insurance of urban employee for inpatient reimbursement; Beijing, PR China. 2010
   Google Scholar
• Beijing Municipal People’s Government. Data on file. Beijing basic medical insurance for urban residents; Beijing, PR China. 2010
   Google Scholar
• Foreign Exchange Rates - H.10 Weekly. Release date 25 Sep 2017. Board of Governors of the Federal Reserve System. Washington DC, USA. https://www.federalreserve.gov/releases/h10/current/
   Google Scholar
• World Health Organization. Cost-effectiveness and strategic planning (WHO-CHOICE); Geneva, Switzerland. 2003. Available at: http://www.who.int/choice/costs/CER_levels/en
   Google Scholar
• Arendrup MC. Candida and candidaemia. Susceptibility and epidemiology. Dan Med J 2013;60:B4698
   PubMed Web of Science ®Google Scholar
• Yapar N. Epidemiology and risk factors for invasive candidiasis. Ther Clin Risk Manag 2014;10:95-105
   PubMed Web of Science ®Google Scholar
• Xiao M, Fan X, Chen SC, et al. Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance. J Antimicrob Chemother 2015;70:802-10
   PubMed Web of Science ®Google Scholar
• Zilderberg MD, Kothari S, Shorr AF, et al. Cost-effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICU-acquired candidemia among patients with sepsis: a model simulation. Crit Care 2009;13:R94
   PubMed Web of Science ®Google Scholar
• Gold M, Siegel J, Russell L, et al. Cost-effectiveness in health and medicine: report of the panel on cost-effectiveness in health and medicine. New York: Oxford University Press; 1996
   Google Scholar
• World Health Organization. Making choices in health: WHO guide to cost-effective analysis. Geneva, Switzerland: WHO; 2003. Available at: www.who.int/choice/publications/p_2003_generalised_cea
   Google Scholar
• Baddley J, Patel M, Bhavnani S, et al. Association of fluconazole pharmacodynamics with mortality in patients with candidemia. Antimicrob Agents Chemother 2008;52:3022-8
   PubMed Web of Science ®Google Scholar